Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Long-Term Investments (2016 - 2023)

Sangamo Therapeutics has reported Long-Term Investments over the past 12 years, most recently at $39.0 million for Q2 2023.

  • Quarterly results put Long-Term Investments at $39.0 million for Q2 2023, down 18.62% from a year ago — trailing twelve months through Jun 2023 was $39.0 million (down 18.62% YoY), and the annual figure for FY2022 was $29.8 million, down 66.15%.
  • Long-Term Investments for Q2 2023 was $39.0 million at Sangamo Therapeutics, up from $35.6 million in the prior quarter.
  • Over the last five years, Long-Term Investments for SGMO hit a ceiling of $95.6 million in Q3 2021 and a floor of $5.0 million in Q1 2020.
  • Median Long-Term Investments over the past 5 years was $44.1 million (2020), compared with a mean of $45.7 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 75.28% in 2019 and later soared 748.62% in 2021.
  • Sangamo Therapeutics' Long-Term Investments stood at $21.8 million in 2019, then soared by 131.45% to $50.5 million in 2020, then skyrocketed by 74.49% to $88.2 million in 2021, then crashed by 66.15% to $29.8 million in 2022, then skyrocketed by 30.8% to $39.0 million in 2023.
  • The last three reported values for Long-Term Investments were $39.0 million (Q2 2023), $35.6 million (Q1 2023), and $29.8 million (Q4 2022) per Business Quant data.